Larimar Therapeutics, Inc. (LRMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.830.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LRMR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Submit all modules of the rolling Biologics License Application (BLA) including the CMC module by second half of 2026 to seek accelerated approval for nomlabofusp.
Stated as a priority in 3 disclosures including 2026-Q1 and mid-2026 updates. Management initiated rolling BLA submission in June 2026 and expects to complete final modules including CMC in second half of 2026. This aligns with the regulatory timeline and trajectory is delivering as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Submission of the final modules including the CMC module expected in second half of 2026”
Provide topline data from the ongoing open-label study to support BLA submission and demonstrate nomlabofusp's safety and efficacy.
Stated in 3 disclosures including 2026-Q1 and mid-2026 updates. Topline OL study data was reported in June 2026 showing sustained skin FXN levels and directional clinical improvements versus natural history. The trajectory matches management's stated goal and shows delivery of clinical data.
“We expect to report topline data from our open-label (OL) study this quarter”
Plan to launch nomlabofusp in the U.S. in the first half of 2027, contingent on regulatory approval.
Stated in 3 disclosures including 2026-Q1 and 2026-Q2 updates. Management consistently targets a U.S. launch in the first half of 2027, contingent on approval. Preparations for commercial activities are underway, indicating progress toward this goal.
“Targeting first half 2027 launch, if approved”
Begin dosing the first patient in the global confirmatory Phase 3 study of nomlabofusp in the third quarter of 2026.
Stated in 3 disclosures including 2026-Q1 and 2026-Q2 updates. Management plans to initiate dosing in the global Phase 3 study in Q3 2026. The repeated statements and current progress indicate the company is delivering on this operational milestone.
“Plan to dose first patient in global confirmatory Phase 3 study in mid-2026”
Ensure sufficient cash and investments to fund operations through at least the third quarter of 2027.
Stated in 3 disclosures including 2026-Q1 and 2026-Q2 updates. Cash and investments decreased from $200.4M at 2026-Q1 to $156.3M at 2026-Q2, with management projecting runway into Q2/Q3 2027. The trajectory shows cash burn but runway remains sufficient as planned.
“$200.4 million in cash with projected runway into second quarter of 2027”
Over the trailing year it converted 1.05x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.